# Nalu Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nalu-medical

- Industry: Medical Devices & Equipment
- Headquarters: Carlsbad, US
- Website: www.nalumed.com
- Total disclosed funding: $155M
- Latest round: Series E (Mar 5, 2024)
- Investors on record: 10

## About

Based in California, US, and founded in 2014, Nalu Medical, Inc. is a MedTech company that engages in the development of neuro-stimulation devices intended to help patients suffering from chronic neuropathic pain. In March 2024, Nalu Medical, Inc. raised USD 20 million in Series E funding from investor B Capital, with participation from returning investors Advent Life Sciences, Aperture Venture Partners, Endeavour Vision, Decheng Capital, Gilde Healthcare Partners, Longitude Capital, MVM Partners, and Pura Vida Investments. As of 2022, the company is being led by its president and CEO, Earl Fender. As of 2022, the company is being led by its president and CEO, Earl Fender.

Nalu Medical, Inc. develops a minimally invasive, battery-free, micro-implantable pulse generator (iPG) to help patients suffering from chronic neuropathic pain. The company’s neurostimulation systems utilize microelectronics concepts for delivering electrical pulses to the neurosystem, thereby regulating the pain signals to the brain to create a reduced pain feeling in the patient. The iPG is implanted into the patient's body using minimal procedures, and the treatment is delivered via an externally worn, easily upgradeable, or replacement therapy disc. The company offers a wide range of therapy options, with a focus on SCS (spinal cord stimulation) and PNS (peripheral nerve stimulation) indications, which can be controlled or adjusted by patients through the company's smartphone application.

The company will use the March 2024 funding to progress its chronic neuropathic pain treatment and its expedited commercial expansion.

In October 2025, Boston Scientific Corporation acquired Nalu Medical, Inc. from Advent Life Sciences, Aperture Venture Partners, BCapital, Decheng Capital, Endeavour Vision, Gilde Healthcare, Longitude Capital, and MVM Partners for an upfront payment of USD 533 million in cash and will received additional payment of approximately USD 600 upon achieving milestones. The acquisition enables Boston Scientific to expand its pain management portfolio by adding Nalu Medical, Inc. peripheral nerve stimulation technology for chronic pain treatment.

## Funding rounds

- Series E, Mar 5, 2024, $20M — MVM Partners, Gilde Healthcare, Aperture Venture Partners, Endeavour Vision, Longitude Capital, Decheng Capital, Pura Vida Investments, B Capital, Advent Life Sciences
- Series E, Dec 21, 2023, $65M — MVM Partners, Gilde Healthcare, Aperture Venture Partners, Novo Holdings, Endeavour Vision, Longitude Capital, Decheng Capital, Pura Vida Investments, Advent Life Sciences
- Series D, Feb 17, 2022, $70M — MVM Partners, Gilde Healthcare, Aperture Venture Partners, Endeavour Vision, Longitude Capital, Decheng Capital, Pura Vida Investments, Advent Life Sciences

## Investors

- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series D, Series E
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series D, Series E
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series D, Series E
- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series D, Series E
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series D, Series E
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series D, Series E
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series D, Series E
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series D, Series E
- Novo Holdings — Series E
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series E